Contents

2216 FHL2 regulates the resolution of tissue damage in chronic inflammatory arthritis

2224 NLRP3 and ASC suppress lupus-like autoimmunity by driving the immunosuppressive effects of TGF-β receptor signalling
M Lech, G Lorentz, O P Kulkarni, M O O Gousar, N Sager, M N Dansegur, R Gauthier, M W M Wintergerst, D Saez, H E Susani, H-J Anden

2236 B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease
E Della-Torre, E Feeney, V Deshpande, H Mattoo, V Mahajan, M Kulikova, Z S Wallace, M Carruthers, R T Chung, S Pillai, J H Stone

2244 Progranulin protects against osteoarthritis through interacting with TNF-α and β-Catenin signalling
Yun-peng Zhao, B Liu, Qing-yun Tan, Jian-lei Wei, B Richbourgh, Chuan-ju Liu

2254 Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis
R F Schelbergen, E J Geven, M H J van den Bosch, H Eriksson, T Leanderson, T Vogl, J Roth, F A J van de Loo, M I Koenders, P M van der Kraan, W B van den Berg, A B Blom, P L E M van Lent

Letters

2260 Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis
N van Herwaarden, C A M Bouman, A van der Maas, R F van Vollenhoven, J W Bijlsma, F H J van den Hoogen, A A den Broeder, B J F van den Bemt

2261 Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment

Electronic pages

Correspondence

e64 The effect of synovial tissue volume shrinking on pain relief for knee osteoarthritis was overestimated or not?
J Wei, C Zeng, Guang-hua Lei

e65 Response to: ‘The effect of synovial tissue volume shrinking on pain relief for knee osteoarthritis was overestimated or not?’ by Wei et al
T W O’Neill, M J Barber, N Manase, J J Marjoribanks, R Hodgson, A D Gatt, T F Coates, C E Hutchinson, D T Felson

e66 The definition of remission in psoriatic arthritis: can this be accurately without assessment of multiple domains?
P S Hellwell, L C Coates

e67 Defining remission and treatment success using the DAPSA score: response to letter by Hellwell and Coates
M M Schuls, D Alcaha, J S Smolen

e68 Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?
L van Hoeven, B W Koos, J AFW Hazes, A EAM Wul

e69 Defining an optimal referral strategy for patients with a suspicion of axial spondyloarthritis: what is really important? Response to: ‘Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?’ by van Hoeven et al
D Poddubnyy, A van Tubergen, R Landewe, J Steyer, D van der Heijde

e70 Role of nerve growth factor and tropomyosin receptor kinase A in the pathogenesis of osteoarthritis. Might nerve growth factor be the link interwining obesity and osteoarthritis?
P iannone, S Perniola, G Lopalco, L Cantarini, G Lapadula

e71 Response to: ‘Role of nerve growth factor (NGF) and tropomyosin receptor kinase A (TrkA) in the pathogenesis of osteoarthritis. Might NGF be the link interwining obesity and OA?’ by iannone et al
L N Nwosu, D A Walsh